UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 139

Sortiert nach

Window of opportunity studies: Do they fulfil our expectations?

Cancer treatment reviews, 2016-02, Vol.43, p.50-57

2016

Volltextzugriff (PDF)

Somatic Uniparental Isodisomy Explains Multifocality of Glomuvenous Malformations

American journal of human genetics, 2013-02, Vol.92 (2), p.188-196

2013

Volltextzugriff (PDF)

The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features

Haematologica (Roma), 2015-03, Vol.100 (3), p.e114

2015

Volltextzugriff (PDF)

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (7), p.597-609

2020

Volltextzugriff (PDF)

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

The Lancet (British edition), 2023-05, Vol.401 (10390), p.1773-1785

2023

Volltextzugriff (PDF)

Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial

PloS one, 2019-12, Vol.14 (12), p.e0225748

2019

Volltextzugriff (PDF)

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

Critical reviews in oncology/hematology, 2023-10, Vol.190, p.104089, Article 104089

2023

Volltextzugriff (PDF)

Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

European journal of cancer (1990), 2022-05, Vol.166, p.300-308

2022

Volltextzugriff (PDF)

Inhibition of Mitochondrial Redox Signaling with MitoQ Prevents Metastasis of Human Pancreatic Cancer in Mice

Cancers, 2022-10, Vol.14 (19), p.4918

2022

Volltextzugriff (PDF)

Colon Cancer: Update on Adjuvant Therapy

Clinical colorectal cancer, 2008-05, Vol.7 (3), p.178-183

2008

Volltextzugriff (PDF)

MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice

Cancers, 2022-03, Vol.14 (6), p.1488

2022

Volltextzugriff (PDF)

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Cancers, 2022-08, Vol.14 (16), p.3876

2022

Volltextzugriff (PDF)

Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families

Breast cancer research : BCR, 2020-04, Vol.22 (1), p.36-36, Article 36

2020

Volltextzugriff (PDF)

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Nature communications, 2023-12, Vol.14 (1), p.8223-8223, Article 8223

2023

Volltextzugriff (PDF)

Interobserver Variability in Ductal Carcinoma In Situ of the Breast

American journal of clinical pathology, 2020-11, Vol.154 (5), p.596-609

2020

Volltextzugriff (PDF)

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Nature communications, 2023-11, Vol.14 (1), p.7018-7018, Article 7018

2023

Volltextzugriff (PDF)

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer

Clinical cancer research, 2021-11, Vol.27 (21), p.5760-5770

2021

Volltextzugriff (PDF)

Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer

Future oncology (London, England), 2024-06, Vol.20 (18), p.1237-1250

2024

Volltextzugriff (PDF)

Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers

Breast cancer research : BCR, 2024-02, Vol.26 (1), p.29-29, Article 29

2024

Volltextzugriff (PDF)

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application

PloS one, 2016-02, Vol.11 (2), p.e0148957-e0148957

2016

Volltextzugriff (PDF)

Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients

Scientific reports, 2021-05, Vol.11 (1), p.9922-9922, Article 9922

2021

Volltextzugriff (PDF)

Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women

Cancers, 2022-12, Vol.15 (1), p.245

2022

Volltextzugriff (PDF)

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

The lancet oncology, 2024-05, Vol.25 (5), p.614-625

2024

Volltextzugriff (PDF)

Cardiac structure, function, and coronary anatomy 10 years after isolated contemporary adjuvant radiotherapy in breast cancer patients with low cardiovascular baseline risk

European heart journal cardiovascular imaging, 2024-04, Vol.25 (5), p.645-656

2024

Volltextzugriff (PDF)

Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Breast cancer research and treatment, 2024, Vol.203 (2), p.351-363

2024

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(128)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(24)
Journal Of Clinical Oncology
(13)
Plos One
(8)
Cancers
(5)
European Journal Of Cancer
(5)
The Journal Of Nuclear Medicine
(5)
Leukemia Research
(4)
Breast
(3)
Breast Cancer Research And Treatment
(3)
Clinical Cancer Research
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Window of opportunity studies: Do they fulfil our expectations?

Somatic Uniparental Isodisomy Explains Multifocality of Glomuvenous Malformations

The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

Inhibition of Mitochondrial Redox Signaling with MitoQ Prevents Metastasis of Human Pancreatic Cancer in Mice

Colon Cancer: Update on Adjuvant Therapy

MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Interobserver Variability in Ductal Carcinoma In Situ of the Breast

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer

Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer

Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application

Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients

Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

Cardiac structure, function, and coronary anatomy 10 years after isolated contemporary adjuvant radiotherapy in breast cancer patients with low cardiovascular baseline risk

Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Suchergebnisse filtern